2026年的早春,全球代谢病药物研发领域便投下了多枚重磅“探路石”。 3月6日,辉瑞宣布国家药品监督管理局(NMPA)已正式批准新一代cAMP偏向型GLP-1受体激动剂埃诺格鲁肽注射液(先维盈®),用于在控制饮食和增加体力活动基础上对成人超重/肥胖患者的长期体重管理。 同一天,丹麦生物技术公司Zealand Pharma公布了其与罗氏合作开发的胰淀素类似物petrelintide治疗肥胖症的2...
Source Link2026年的早春,全球代谢病药物研发领域便投下了多枚重磅“探路石”。 3月6日,辉瑞宣布国家药品监督管理局(NMPA)已正式批准新一代cAMP偏向型GLP-1受体激动剂埃诺格鲁肽注射液(先维盈®),用于在控制饮食和增加体力活动基础上对成人超重/肥胖患者的长期体重管理。 同一天,丹麦生物技术公司Zealand Pharma公布了其与罗氏合作开发的胰淀素类似物petrelintide治疗肥胖症的2...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.